Curevac announces promising phase 2 interim data from seasonal influenza vaccine development program in collaboration with gsk

Potentially differentiated, multivalent candidate encodes antigens matched to all four who-recommended flu strains for influenza a strains, geometric mean titers numerically exceeded those elicited by the licensed comparator vaccines consistently across all tested dose levels and age groups for influeseasonal flu vaccine candidate boosted antibody titers at all dose levels and for all encoded seasonal influenza strains across younger and older adults nza b strains, geometric mean titers were lower than those elicited by the licensed comparator vaccines, in line with expectations and other initial mrna-based clinical flu development programs further optimizations to enhance immune responses against influenza b strains will be tested in additional phase 2 study candidate showed acceptable safety profile, confirming previous findings that the proprietary platform elicits strong overall antibody titers at well-tolerated dose levels tÜbingen, germany and boston, ma / accesswire / april 4, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced interim data from an ongoing phase 2 part of the combined phase 1/2 study of its seasonal influenza vaccine candidate, conducted in collaboration with gsk.
CVAC Ratings Summary
CVAC Quant Ranking